T2 Biosystems (TTOO) said Monday it was starting a multi-year distribution agreement with Cardinal Health (CAH), which will exclusively sell its direct-from-blood diagnostics equipment for the rapid detection of sepsis-causing pathogens.
Among the devices included under the new agreements are T2 Biosystems' US Food and Drug Administration-authorized T2Dx Instrument, T2Bacteria Panel and the T2Candida Panel. Financial terms and other details of the new contract were not disclosed.
Price: 111.65, Change: -0.34, Percent Change: -0.30
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。